ResMed Inc. (RMD)
NYSE · Health Care · market cap 32.56B
Share price
$228.42
At the last nightly close
Intrinsic value
$288.02
Range $205.73 – $217.75 before any credit for growth. The figure above credits what the franchise record earns, which is why it sits outside that range.
Margin of safety
+26.1%
($288.02 − $228.42) ÷ $228.42
EV / EBIT
55.1
On the median operating profit of 15 fiscal years through 2026.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.
The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-07.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2026-FY | 5.65B | 1.91B | 1.52B | n/a | 1.63B |
| 2025-FY | 5.15B | 1.69B | 1.40B | n/a | 1.65B |
| 2024-FY | 4.69B | 1.38B | 1.02B | 6.94 | 1.29B |
| 2023-FY | 4.22B | 1.15B | 897.6M | 6.12 | 559.3M |
| 2022-FY | 3.58B | 1.00B | 779.4M | 5.30 | 216.3M |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- ResMed Inc. (RMD) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
- ResMed (NYSE:RMD) - Stock Analysis - Simply Wall Stsimplywall.st
- ResMed (RMD) Q4 Earnings and Revenues Top Estimatesfinance.yahoo.com
- RMD Press Releases Resmedmarketchameleon.com
- ResMed Inc. (RMD)investor.resmed.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on RMD.
Run the board on RMD10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.